Muscle Disease Group Musculoskeletal Translational Medicine, Novartis Institutes for Biomedical Research, Cambridge, Massachusetts, USA.
Ann N Y Acad Sci. 2010 Nov;1211:25-36. doi: 10.1111/j.1749-6632.2010.05809.x.
The recent advances in our understanding of the biology of muscle, and how anabolic and catabolic stimuli interact to control muscle mass and function, have led to new interest in pharmacological treatment of muscle wasting. Loss of muscle occurs as a consequence of many chronic diseases (cachexia), as well as normal aging (sarcopenia). Although anabolic effects of exercise on muscle have been know for many years, the development of pharmacological treatment for muscle loss is in its infancy. However, there is growing excitement among researchers in this field that developments may yield new treatments for muscle wasting in the future.
最近我们对肌肉生物学的理解取得了进展，以及合成代谢和分解代谢刺激如何相互作用来控制肌肉质量和功能，这导致人们对肌肉减少症的药物治疗产生了新的兴趣。肌肉减少症是许多慢性疾病（恶病质）以及正常衰老（肌肉减少症）的结果。虽然运动对肌肉的合成代谢作用已经为人所知多年，但肌肉减少症的药物治疗仍处于起步阶段。然而，该领域的研究人员越来越兴奋，认为这方面的发展可能会在未来产生新的肌肉减少症治疗方法。
